These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
831 related articles for article (PubMed ID: 31958182)
1. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer. Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182 [TBL] [Abstract][Full Text] [Related]
2. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865 [TBL] [Abstract][Full Text] [Related]
3. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910 [TBL] [Abstract][Full Text] [Related]
5. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. Cerrato A; Morra F; Celetti A J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198 [TBL] [Abstract][Full Text] [Related]
6. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. Okuma HS; Yonemori K Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689 [TBL] [Abstract][Full Text] [Related]
7. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619 [TBL] [Abstract][Full Text] [Related]
8. Homologous recombination deficiency in triple negative breast cancer. Belli C; Duso BA; Ferraro E; Curigliano G Breast; 2019 Jun; 45():15-21. PubMed ID: 30818144 [TBL] [Abstract][Full Text] [Related]
9. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer. Tazzite A; Jouhadi H; Benider A; Nadifi S Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831 [TBL] [Abstract][Full Text] [Related]
10. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Tutt A; Tovey H; Cheang MCU; Kernaghan S; Kilburn L; Gazinska P; Owen J; Abraham J; Barrett S; Barrett-Lee P; Brown R; Chan S; Dowsett M; Flanagan JM; Fox L; Grigoriadis A; Gutin A; Harper-Wynne C; Hatton MQ; Hoadley KA; Parikh J; Parker P; Perou CM; Roylance R; Shah V; Shaw A; Smith IE; Timms KM; Wardley AM; Wilson G; Gillett C; Lanchbury JS; Ashworth A; Rahman N; Harries M; Ellis P; Pinder SE; Bliss JM Nat Med; 2018 May; 24(5):628-637. PubMed ID: 29713086 [TBL] [Abstract][Full Text] [Related]
11. Biology and Management of Patients With Triple-Negative Breast Cancer. Sharma P Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886 [TBL] [Abstract][Full Text] [Related]
12. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy. Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975 [TBL] [Abstract][Full Text] [Related]
13. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517 [TBL] [Abstract][Full Text] [Related]
15. Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness. Darbeheshti F; Kadkhoda S; Keshavarz-Fathi M; Razi S; Bahramy A; Mansoori Y; Rezaei N BMC Cancer; 2022 Jun; 22(1):668. PubMed ID: 35715772 [TBL] [Abstract][Full Text] [Related]
16. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. Xia Q; Cai Y; Peng R; Wu G; Shi Y; Jiang W Int J Oncol; 2014 Mar; 44(3):735-44. PubMed ID: 24378347 [TBL] [Abstract][Full Text] [Related]
17. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466 [TBL] [Abstract][Full Text] [Related]
18. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality. Murai J; Pommier Y Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596 [TBL] [Abstract][Full Text] [Related]
19. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989 [TBL] [Abstract][Full Text] [Related]
20. DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors. Shi Y; Jin J; Wang X; Ji W; Guan X Neoplasia; 2019 Jun; 21(6):533-544. PubMed ID: 31029033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]